Nutriband Updates Shareholders on Key Milestones and New Directors Appointment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2026
0mins
Nutriband has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting. Addition of Two New Directors: Allesandro Puddu and Viorica Carlig added as two new directors. 2025 Aversa Fentanyl Development Summary: Strengthened collaboration with Kindeva through an exclusive product development partnership; Granted patent protecting its Aversa abuse deterrent platform technology in Macao; Completed commercial manufacturing process scale-up with partner Kindeva for Aversa Fentanyl; Issued new US patent which further expands Nutriband's intellectual property protection in the United States; Held Type C meeting with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for Aversa Fentanyl; Filed a new provisional patent application with the U.S. Patent and Trademark Office covering improved aversive formulations and coating application methods; Initiated development of the worldwide commercial brand name and visual identity for Aversa Fentanyl with Brand Institute. 2026 Aversa Fentanyl Focus on Development Towards NDA Filing: File nonprovisional patent application to potentially extend patent protection of Aversa technology-based products to 2046; Manufacture clinical supplies for the Human Abuse Liability clinical trial; File Investigational New Drug application with the US FDA; Initiate Human Abuse Liability clinical study. EarthVision Bio Purchase of Pocono Pharma: The full purchase price and closing for the proposed sale of our Pocono subsidiary has not been received as of the shareholder meeting on Jan 24, 2026. However, the Company is collecting on the agreed nonrefundable $10,000 USD weekly penalty and has so far collected $30,000 USD of payments to extend the closing date.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRB
Wall Street analysts forecast NTRB stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.490
Low
15.00
Averages
15.00
High
15.00
Current: 3.490
Low
15.00
Averages
15.00
High
15.00
No data
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nutriband Showcases AI Wellness Product Portfolio at ECRM Conference
- Product Portfolio Expansion: Nutriband's Active Intelligence subsidiary will showcase its latest AI wellness product portfolio at the ECRM conference in June 2026, including upcoming launches of AI Performance Tape, AI Energy Patches, and AI Sleep products, aimed at meeting the growing consumer demand for health and recovery solutions, thereby enhancing market competitiveness.
- Retail Collaboration Opportunities: The company plans to meet with buyers from Walmart, Walgreens, Amazon, and other major retailers during the conference, actively seeking new retail partnerships and distribution opportunities to expand its influence in the rapidly growing wellness market.
- Growing Market Demand: CEO Gareth Sheridan stated that consumer demand for wellness, recovery, and performance solutions is accelerating, and the company believes its AI product platform is well-positioned to capitalize on these long-term market trends, driving future sales growth.
- Technological Innovation: Nutriband's AVERSA™ abuse-deterrent transdermal technology aims to enhance drug safety by preventing abuse and misuse, which is expected to provide strong technical support for its development of an abuse-deterrent fentanyl patch, further solidifying its position in the pharmaceutical industry.
See More
NUTRIBAND INC - NAME CHOSEN FOR REGISTRATION WITH US PATENT AND TRADEMARK OFFICE
- Patent and Trademark Office Submission: A list of selected names has been submitted to the U.S. Patent and Trademark Office for registration.
- Nutriband Inc.: The submission is related to the company Nutriband Inc., indicating potential new branding or product developments.
See More
NUTRIBAND INC CHOOSES BRAND NAME FOR ABUSE-RESISTANT FENTANYL PATCH; PLANS FDA SUBMISSION
Commercial Brand Name Selection: Nutriband has chosen a commercial brand name for its fentanyl patch, which is intended for abuse deterrence.
Submission to FDA: The company plans to submit this new product to the FDA for approval, aiming to enhance safety and reduce misuse.
See More
Nutriband Annual Meeting Update: New Directors and Product Developments
- New Director Appointments: At the Annual Shareholders Meeting on January 24, 2026, Nutriband appointed two new directors, Alessandro Puddu and Viorica Carlig, with Puddu bringing over 10 years of experience in audit and financial reporting, while Carlig adds extensive leadership and compliance expertise, enhancing the company's governance and strategic execution capabilities.
- AVERSA™ FENTANYL Progress: Strengthened collaboration with Kindeva for the exclusive product development of AVERSA™ FENTANYL, where both parties share development costs in exchange for milestone payments, which is expected to accelerate product commercialization and enhance market competitiveness.
- Patent Protection Expansion: Nutriband secured a patent for its AVERSA™ abuse deterrent platform technology in Macao, further solidifying its intellectual property and providing legal protection for global market expansion.
- Shareholder Complaint and Penalties: The company filed a complaint with FINRA to investigate suspected naked short selling and has collected $30,000 in penalties to extend the closing date, which will help protect shareholder interests and bolster market confidence.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Enhanced Shareholder Value: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M is expected to add $5M to the bottom line without diluting shareholders, demonstrating the company's commitment to maximizing shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, which further enhances returns for investors and strengthens shareholder loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying a solid foundation for future commercialization, showcasing the company's innovative capabilities in drug safety technology.
- Index Inclusion Expansion: In 2025, Nutriband was added to four major indexes, including the Russell Microcap and Russell 3000E, which enhances the company's market visibility and investor interest, likely attracting more attention from potential investors.
See More
Nutriband Showcases AI Wellness Product Portfolio at ECRM Conference
- Product Portfolio Expansion: Nutriband's Active Intelligence subsidiary will showcase its latest AI wellness product portfolio at the ECRM conference in June 2026, including upcoming launches of AI Performance Tape, AI Energy Patches, and AI Sleep products, aimed at meeting the growing consumer demand for health and recovery solutions, thereby enhancing market competitiveness.
- Retail Collaboration Opportunities: The company plans to meet with buyers from Walmart, Walgreens, Amazon, and other major retailers during the conference, actively seeking new retail partnerships and distribution opportunities to expand its influence in the rapidly growing wellness market.
- Growing Market Demand: CEO Gareth Sheridan stated that consumer demand for wellness, recovery, and performance solutions is accelerating, and the company believes its AI product platform is well-positioned to capitalize on these long-term market trends, driving future sales growth.
- Technological Innovation: Nutriband's AVERSA™ abuse-deterrent transdermal technology aims to enhance drug safety by preventing abuse and misuse, which is expected to provide strong technical support for its development of an abuse-deterrent fentanyl patch, further solidifying its position in the pharmaceutical industry.
See More
NUTRIBAND INC - NAME CHOSEN FOR REGISTRATION WITH US PATENT AND TRADEMARK OFFICE
- Patent and Trademark Office Submission: A list of selected names has been submitted to the U.S. Patent and Trademark Office for registration.
- Nutriband Inc.: The submission is related to the company Nutriband Inc., indicating potential new branding or product developments.
See More
NUTRIBAND INC CHOOSES BRAND NAME FOR ABUSE-RESISTANT FENTANYL PATCH; PLANS FDA SUBMISSION
Commercial Brand Name Selection: Nutriband has chosen a commercial brand name for its fentanyl patch, which is intended for abuse deterrence.
Submission to FDA: The company plans to submit this new product to the FDA for approval, aiming to enhance safety and reduce misuse.
See More
Nutriband Annual Meeting Update: New Directors and Product Developments
- New Director Appointments: At the Annual Shareholders Meeting on January 24, 2026, Nutriband appointed two new directors, Alessandro Puddu and Viorica Carlig, with Puddu bringing over 10 years of experience in audit and financial reporting, while Carlig adds extensive leadership and compliance expertise, enhancing the company's governance and strategic execution capabilities.
- AVERSA™ FENTANYL Progress: Strengthened collaboration with Kindeva for the exclusive product development of AVERSA™ FENTANYL, where both parties share development costs in exchange for milestone payments, which is expected to accelerate product commercialization and enhance market competitiveness.
- Patent Protection Expansion: Nutriband secured a patent for its AVERSA™ abuse deterrent platform technology in Macao, further solidifying its intellectual property and providing legal protection for global market expansion.
- Shareholder Complaint and Penalties: The company filed a complaint with FINRA to investigate suspected naked short selling and has collected $30,000 in penalties to extend the closing date, which will help protect shareholder interests and bolster market confidence.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Enhanced Shareholder Value: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M is expected to add $5M to the bottom line without diluting shareholders, demonstrating the company's commitment to maximizing shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, which further enhances returns for investors and strengthens shareholder loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying a solid foundation for future commercialization, showcasing the company's innovative capabilities in drug safety technology.
- Index Inclusion Expansion: In 2025, Nutriband was added to four major indexes, including the Russell Microcap and Russell 3000E, which enhances the company's market visibility and investor interest, likely attracting more attention from potential investors.
See More
